Fact-checked by Grok 2 weeks ago

Dyssomnia

Dyssomnia is a historical term for a broad category of primary disorders affecting the quantity, quality, or timing of , leading to difficulties initiating or maintaining or excessive daytime sleepiness; in modern classifications like the ICSD-3-TR (2023), these are encompassed within sleep-wake disorders. These disorders affect an estimated 50 to 70 million adults in the United States as of 2023, contributing to significant daytime impairments such as fatigue, reduced concentration, and increased risk of accidents. Unlike parasomnias, which involve abnormal behaviors or movements during sleep, dyssomnias primarily disrupt the -wake cycle without such irregularities. In traditional classifications (e.g., ICSD-2), dyssomnias are divided into three main subcategories based on their origins: intrinsic, extrinsic, and disorders (see Historical and Current Classification for modern details). Intrinsic dyssomnias arise from internal physiological issues, including conditions like , , , (RLS), and (PLMD). For instance, involves repeated pauses in breathing due to airway blockage, while RLS causes uncomfortable sensations in the legs that worsen at night and are relieved by movement. Extrinsic dyssomnias result from external factors, such as inadequate , environmental disturbances, or substances like and , which can often be addressed through adjustments. dyssomnias stem from misalignments in the body's internal clock, exemplified by , , or delayed sleep phase syndrome, where sleep patterns fail to synchronize with societal or environmental demands. Common symptoms across dyssomnias include prolonged time to fall asleep, frequent awakenings, non-restorative , and excessive daytime , which can exacerbate underlying health issues like or disorders (see Clinical Features and ). Causes vary widely but often involve a combination of genetic predispositions, neurological factors, and lifestyle influences; for example, may link to brain signaling abnormalities that also affect conditions like (see and Risk Factors). typically requires a detailed sleep history, polysomnography (), or to monitor patterns objectively. Treatment approaches are tailored to the specific type and underlying cause, emphasizing non-pharmacological interventions first, such as (CBT-I), (CPAP) for , or chronotherapy for circadian disruptions (see and ). Medications like hypnotics or stimulants may be used short-term, but improving —maintaining consistent sleep schedules, creating a conducive sleep environment, and avoiding stimulants—is foundational for management. Early intervention is crucial, as untreated dyssomnias can lead to chronic health complications and diminished .

Overview and Classification

Definition

Dyssomnia serves as an umbrella term encompassing a broad category of sleep disorders characterized by difficulties in initiating or maintaining , achieving restorative , or experiencing due to insufficient quantity or quality. These conditions primarily disrupt the normal processes of onset, continuity, or depth, often resulting from intrinsic physiological factors, extrinsic influences, or disturbances. Key characteristics of dyssomnias include persistent alterations in timing, , or that extend beyond typical individual variations in sleep needs and lead to notable daytime consequences, such as impaired cognitive , disturbances, or reduced . In contrast to parasomnias, which involve undesirable physical events, experiences, or behaviors occurring predominantly during transitions or specific sleep stages, dyssomnias focus on quantitative or qualitative deficiencies in the sleep period itself without prominent abnormal motor or experiential phenomena. The term dyssomnia first appeared in the DSM-III-R (1987), where it categorized primary sleep disturbances based on issues with sleep amount or quality, and was subsequently incorporated into early editions of the (ICSD, 1990), grouping related conditions under a similar framework to facilitate diagnosis. Although the specific label has evolved, modern systems like the ICSD-3-TR (2023) retain the foundational emphasis on these sleep quantity and quality disruptions within refined diagnostic categories.

Historical and Current Classification

The classification of dyssomnia emerged in the revised third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), published in 1987 by the , where sleep disorders were organized into three primary categories: dyssomnias (encompassing disturbances in the amount, quality, or timing of ), parasomnias (abnormal behaviors or events during ), and sleep disorders secondary to medical or psychiatric conditions. This framework marked the first formal recognition of dyssomnia as a distinct group, emphasizing primary sleep pathologies independent of other health issues, and laid the groundwork for subsequent specialized classifications in . The (ICSD), first published in 1990 by the (AASM), expanded on the DSM-III-R by introducing a detailed for dyssomnias, subdividing them into three subtypes: intrinsic (internal abnormalities such as psychophysiologic or ), extrinsic (external influences like inadequate or environmental factors), and disorders (timing misalignments including delayed sleep phase syndrome). This structure utilized a three-axis diagnostic system—covering the itself, associated procedures, and comorbid conditions—to enhance clinical and research consistency, replacing the earlier 1979 Diagnostic Classification of Sleep and Arousal Disorders. The 1997 revision of ICSD-1 refined criteria but retained the core dyssomnia framework. In 2005, ICSD-2 further evolved the classification by reorganizing dyssomnias into more granular major categories—insomnias, sleep-related breathing disorders, hypersomnias of central origin, and sleep-wake disorders—while eliminating the broad dyssomnia umbrella to better accommodate heterogeneous symptom presentations and incorporate emerging polysomnographic evidence. This edition listed 81 diagnostic categories overall, shifting to a single-axis focus on diagnosis alone for improved usability, and addressed limitations in the prior system's ability to capture comorbid or multifaceted etiologies. The 2014 ICSD-3 marked a significant shift by de-emphasizing dyssomnia entirely as a standalone category, instead integrating its components into seven evidence-based groups: insomnia disorders, sleep-related breathing disorders, central disorders of hypersomnolence, sleep-wake disorders, parasomnias, sleep-related , and other sleep disorders, to align with advances in neurobiology, , and harmonization with DSM-5. Key changes included removing outdated subtypes like sleep state misperception (reclassified within or as insufficient sleep syndrome) and emphasizing phenotypic specificity over broad groupings, supported by updated literature reviews. The 2023 text revision (ICSD-3-TR) consolidated to six categories by eliminating the "other" group, further refining criteria with recent genetic and pathophysiological insights while maintaining the disorder-specific approach to enhance diagnostic reliability.

Clinical Features and Diagnosis

Symptoms

Dyssomnias are characterized by primary disturbances in the quantity, quality, or timing of sleep, manifesting as or . Core symptoms include difficulty initiating sleep (sleep-onset ), frequent nocturnal awakenings (sleep-maintenance ), early morning awakenings with inability to return to sleep, non-restorative sleep despite adequate duration, excessive daytime sleepiness, or involving prolonged sleep periods. These sleep-related issues often persist for at least three months and occur despite opportunities for sufficient rest. In the ICSD-3-TR classification, such symptoms fall under categories like disorders and central disorders of hypersomnolence. Daytime consequences of dyssomnias significantly impair functioning, including chronic fatigue, reduced concentration and cognitive performance, mood disturbances such as and depressive symptoms, diminished at work or school, and elevated risk of accidents due to sleepiness. For instance, can lead to episodes, increasing errors in tasks requiring vigilance. In cases involving circadian rhythm dyssomnias, symptoms intensify with disruptions to the sleep-wake cycle, such as or , resulting in worsened or sleepiness misaligned with societal schedules. Chronic from dyssomnias contributes to broader quality-of-life impairments, including heightened anxiety, cardiovascular strain through elevated and , and weakened immune function increasing susceptibility to infections.

Diagnostic Approaches

The of dyssomnia begins with a comprehensive initial evaluation focused on gathering detailed information about the 's sleep patterns and overall . This typically involves obtaining a thorough sleep history through patient interviews, which explore the onset, duration, and nature of sleep complaints, as well as associated daytime functioning. Sleep diaries, maintained by the patient for at least one to two weeks, provide prospective data on bedtime, wake time, sleep latency, awakenings, and total time, helping to identify patterns not captured in retrospective recall. Standardized questionnaires are integral to this process; the (ESS) assesses sleepiness by rating the likelihood of dozing in eight common situations, with scores above 10 indicating excessive sleepiness, while the (PSQI) evaluates overall sleep quality over the past month, with global scores greater than 5 suggesting poor sleep. Additionally, clinicians systematically rule out medical comorbidities (such as disorders or ) and psychiatric conditions (like or anxiety) through physical examinations, laboratory tests, and screenings, as these can mimic or exacerbate dyssomnia symptoms. Diagnosis adheres to the criteria outlined in the , Third Edition, Text Revision (ICSD-3-TR), which categorizes dyssomnias under domains such as , central disorders of hypersomnolence, sleep-related breathing disorders, and sleep-wake disorders. Core requirements across these include symptoms persisting for at least three months (for chronic forms like ), significant distress or impairment in social, occupational, or other areas of functioning, and the exclusion of alternative explanations such as other sleep disorders, medical conditions, psychiatric disorders, or substance effects. For instance, chronic disorder requires dissatisfaction with sleep quantity or quality occurring at least three nights per week, accompanied by daytime consequences, and not attributable to circadian misalignment or inadequate alone. These criteria ensure a standardized, evidence-based framework for confirming dyssomnia while avoiding . Objective testing complements subjective reports to quantify sleep disturbances and confirm ICSD-3-TR criteria. (PSG), the gold-standard overnight study, records physiological variables like brain waves, eye movements, muscle activity, and to analyze sleep architecture, identifying abnormalities such as reduced in hypersomnias or apneic events in breathing-related dyssomnias. The (MSLT), performed the day after PSG, measures the time to fall asleep during four to five scheduled naps, with mean latencies under eight minutes and sleep-onset REM periods supporting diagnoses like within hypersomnolence disorders. , using a wrist-worn device to monitor rest-activity cycles over one to two weeks, is particularly useful for evaluating dyssomnias by estimating sleep-wake patterns and entraining behaviors without the need for laboratory settings. These tools are selected based on the suspected dyssomnia subtype, with PSG and MSLT reserved for cases where history and questionnaires suggest central hypersomnolence or complex breathing issues. Differential diagnosis is essential to distinguish dyssomnias from parasomnias (e.g., sleepwalking) or substance-induced sleep issues, often involving targeted assessments to exclude mimics. For suspected sleep-related breathing dyssomnias, home sleep apnea testing (HSAT) provides a cost-effective alternative to PSG, monitoring airflow, oxygen saturation, and effort to detect apneas or hypopneas without full polysomnographic setup, particularly in uncomplicated adult cases. This stepwise approach ensures dyssomnias are not misattributed to non-sleep factors, with iterative testing refining the diagnosis as needed.

Etiology and Risk Factors

Biological and Genetic Factors

Dyssomnias arise from dysregulation in the neural circuits governing sleep-wake transitions, primarily involving imbalances in key neurotransmitters. (also known as hypocretin), produced by neurons in the , promotes and stabilizes arousal states; its deficiency disrupts architecture, leading to as seen in certain hypersomnias. Complementarily, gamma-aminobutyric acid (), the primary inhibitory , is released by sleep-promoting neurons in the preoptic and to suppress wake-promoting systems, facilitating onset and maintenance. Disruptions in these orexin-GABA interactions contribute to the fragmented patterns characteristic of dyssomnias. Genetic factors play a significant role in dyssomnia susceptibility, with heritability estimates for chronic insomnia ranging from 30% to 50% based on twin and family studies. genes, such as PER (period) and CLOCK, regulate the molecular feedback loops that synchronize -wake rhythms; mutations in these genes, including missense variants in PER3 and CRY1, have been linked to advanced or delayed phase disorders within the dyssomnia spectrum. In type 1, a specific exists with the *06:02 allele, present in nearly all cases and conferring over 20-fold increased risk through immune-mediated loss. Familial aggregation is also evident in conditions like , underscoring polygenic influences on dyssomnia . Hormonal imbalances further underpin dyssomnia , particularly involving the interplay between and . , a regulated by the hypothalamic-pituitary-adrenal axis, exhibits a diurnal rhythm that peaks in the morning to promote , while elevated evening levels can inhibit secretion from the , delaying initiation. , in turn, signals circadian alignment for ; its reduced nocturnal surge in dyssomnias correlates with prolonged sleep latency and poor efficiency. Neurologically, the integrates these signals via the for circadian timing, while brainstem nuclei like the and modulate arousal through noradrenergic and projections. Dysfunctions in these regions impair , exacerbating dyssomnia symptoms. Comorbid medical conditions often intersect with dyssomnia through shared biological pathways. Neurological disorders such as are associated with dyssomnias due to degeneration in systems affecting sleep regulation in the and . Endocrine disruptions, including dysfunction, contribute intrinsically; elevates risk for sleep disturbances via altered metabolic and hormonal signaling that influences hypothalamic sleep centers. similarly heightens dyssomnia prevalence by accelerating arousal pathways. These links highlight how underlying physiological derangements can precipitate or worsen sleep-wake dysregulation.

Environmental and Behavioral Factors

Environmental and behavioral factors play a significant role in the development and exacerbation of dyssomnias, which encompass disorders characterized by difficulties in initiating or maintaining , or . Poor , including irregular sleep schedules and excessive before bed, disrupts the natural sleep-wake cycle and contributes to insomnia-like symptoms in dyssomnias. For instance, exposure to from screens suppresses production, delaying sleep onset and reducing overall quality. Similarly, consumption of and interferes with sleep architecture; blocks receptors to prolong alertness, while fragments sleep stages despite initial sedation, leading to poorer sleep continuity. External environmental triggers further compound these issues by altering sleep initiation and maintenance. Noise pollution, particularly from urban traffic or transportation, increases sleep disturbances by causing frequent arousals and heightened sympathetic activity, even if individuals do not fully awaken. Light pollution from artificial sources mimics daylight, suppressing melatonin and contributing to circadian misalignment, which manifests as delayed sleep onset in dyssomnias. Extreme temperatures in the sleeping environment also impair sleep efficiency by activating thermoregulatory responses that conflict with the body's cooling needs for rest. Additionally, shift work and frequent travel induce circadian rhythm disruptions, resulting in circadian rhythm dyssomnias like shift work disorder, where misalignment between work schedules and biological clocks leads to chronic sleep deficits. Psychological factors, such as , anxiety, and , act as behavioral amplifiers in dyssomnias by fostering conditioned arousal, where anticipatory worry about sleep perpetuates . These conditions heighten hyperarousal states, making it harder to relax and enter , and often create a vicious cycle where poor sleep worsens emotional distress. Socioeconomic influences, including high work demands and urban living, elevate exposure to dyssomnia disruptors and limit opportunities for restorative sleep. Long or irregular working hours correlate with shortened sleep duration and increased disturbances, particularly among lower-income groups facing multiple jobs or . Urban environments amplify risks through heightened and , which independently associate with poorer sleep quality and higher insomnia prevalence in disadvantaged communities. These modifiable factors often interact with biological vulnerabilities to heighten dyssomnia risk, underscoring the importance of lifestyle awareness for prevention.

Types

Note: The classification into intrinsic, extrinsic, and circadian rhythm dyssomnias follows the traditional framework of the , Second Edition (ICSD-2, 2005). The current ICSD-3-TR (2023) reorganizes sleep disorders into categories such as Disorders, Central Disorders of Hypersomnolence, and Sleep-Wake Disorders, without using the terms "dyssomnia," "intrinsic," or "extrinsic."

Intrinsic Dyssomnias

Intrinsic dyssomnias represent a category of sleep disorders arising from internal physiological abnormalities within the body, independent of external environmental or behavioral influences. These conditions stem from inherent dysfunctions in the mechanisms regulating -wake cycles, often involving neurological or genetic factors that disrupt normal sleep architecture. Unlike extrinsic dyssomnias, which are triggered by outside agents, intrinsic forms originate from the body's own regulatory failures, leading to either excessive sleepiness or difficulties maintaining . Key examples of intrinsic dyssomnias include primary insomnia, (OSA), , , and (RLS) along with its associated (PLMD). Primary insomnia, also known as chronic insomnia disorder, involves persistent difficulty initiating or maintaining sleep due to hyperarousal in the , often without identifiable external causes, leading to daytime impairments. features repeated episodes of partial or complete upper airway obstruction during sleep, resulting in apneic events, oxygen desaturation, and fragmented sleep, primarily due to anatomical and neuromuscular factors. Narcolepsy is characterized by sudden sleep attacks and cataplexy, a sudden loss of triggered by emotions, resulting from a deficiency in (), a essential for promotion. This deficiency arises from the selective loss of -producing neurons in the . Additionally, narcolepsy shows strong genetic predispositions, particularly associations with *06:02 alleles, which increase susceptibility through immune-mediated mechanisms. Idiopathic hypersomnia involves prolonged nocturnal sleep durations exceeding 10 hours, accompanied by unrefreshing sleep and that persists despite extended rest. Naps in this disorder are typically long but fail to alleviate , distinguishing it from other hypersomnias. The underlying remains largely idiopathic, though it is considered a disorder impairing arousal systems without identifiable deficits. Restless legs syndrome manifests as an irresistible urge to move the legs, accompanied by uncomfortable sensorimotor sensations that worsen during periods of rest or inactivity, particularly in the evening. This often leads to sleep-onset . Closely related, features repetitive, involuntary limb jerks during sleep, occurring every 20-40 seconds and potentially fragmenting sleep architecture. Both conditions involve pathway dysfunctions in the and have genetic components, with familial clustering observed in up to 60% of cases. Pathophysiologically, intrinsic dyssomnias often involve neurological impairments in sleep regulation, such as hypothalamic lesions in or altered iron metabolism affecting signaling in RLS/PLMD. Genetic factors play a prominent role, exemplified by the near-universal HLA association in orexin-deficient and polymorphisms in RLS-related genes like BTBD9. These disorders are typically chronic, necessitating lifelong strategies, including symptomatic to mitigate impacts on daily functioning. varies, with affecting approximately 0.02-0.05% of the general population.

Extrinsic Dyssomnias

Extrinsic dyssomnias, also known as extrinsic sleep disorders, are a category of sleep disturbances primarily triggered by identifiable external factors that interfere with initiation, maintenance, or quality, distinguishing them from intrinsic conditions rooted in internal physiological processes. These disorders are often reversible upon removal or modification of the precipitating external agent, emphasizing the role of environmental, behavioral, or substance-related influences in their etiology. In earlier classifications such as the ICSD (2005), extrinsic dyssomnias encompassed conditions where external elements directly disrupt normal architecture, leading to complaints of or . Key examples include inadequate , where lifestyle choices such as irregular bedtimes, excessive consumption, or before bed curtail sufficient sleep opportunity and fragment rest. Environmental insomnia arises from external perturbations like persistent noise, bright light, or uncomfortable temperatures that repeatedly arouse individuals from sleep, preventing consolidated nocturnal rest. Toxin-induced sleep issues, such as those from alcohol withdrawal or medication side effects, further illustrate this category; for instance, alcohol withdrawal provokes acute through heightened excitability and rebound hyperactivity following chronic suppression. Similarly, beta-blockers can induce by inhibiting synthesis, a key regulator of the sleep-wake cycle, resulting in prolonged and reduced sleep efficiency. The mechanisms underlying extrinsic dyssomnias involve direct external interference with sleep physiology, often altering thresholds or neurotransmitter balance to produce fragmented sleep patterns. Stimulants like , for example, prolong sleep latency by blocking receptors and enhancing vigilance, while triggers frequent micro-arousals that disrupt slow-wave and REM sleep stages. In substance-related cases, toxins such as initially promote sedation via enhancement but later cause and hyperarousal during , exacerbating sleep continuity issues. These disruptions are typically acute and dose-dependent, with resolution tied to cessation of exposure. External factors may briefly interact with biological vulnerabilities, such as heightened sensitivity in certain individuals, to amplify effects, though the primary causation remains extrinsic. Clinically, extrinsic dyssomnias are prevalent in acute settings, such as post-surgical recovery or environments, where identifying and eliminating the external trigger—through education, environmental modifications, or substance discontinuation—facilitates rapid improvement. Diagnostic evaluation often relies on sleep history and to confirm the reversible nature of symptoms, avoiding unnecessary pharmacological intervention in favor of targeted behavioral adjustments. is generally favorable, with most cases resolving fully once the extrinsic factor is addressed, underscoring the importance of a thorough environmental in practice.

Circadian Rhythm Disorders

Circadian rhythm sleep disorders (CRSDs) involve disruptions in the 24-hour sleep-wake cycle resulting from desynchronization between the endogenous and external environmental cues. These disorders arise when the internal , which regulates timing, fails to align with societal or required schedules, leading to persistent mismatches in sleep onset and offset. The central circadian pacemaker, located in the (SCN) of the , orchestrates these rhythms through neural and hormonal signals, including the regulation of secretion from the . Light exposure, particularly in the evening, suppresses melatonin production via the , which can exacerbate desynchronization in susceptible individuals. Key subtypes include delayed sleep-wake phase disorder (DSWPD), characterized by a delayed sleep onset and preference for later wake times, often prevalent among adolescents and young adults due to a phase delay in the . In contrast, advanced sleep-wake phase disorder (ASWPD) features an earlier-than-desired sleep onset and awakening, typically accompanied by early evening sleepiness, and is more common in older adults with a phase-advanced . Shift work disorder manifests as recurrent and excessive sleepiness in individuals working non-standard hours, such as night or rotating shifts, where the work schedule conflicts with the endogenous . Jet lag disorder, a transient form, occurs after rapid travel across multiple time zones, causing temporary misalignment of the internal clock with the new environment, resulting in difficulties initiating or maintaining alertness. Clinically, these disorders present with insomnia during attempted sleep at conventional times and hypersomnolence during undesired periods, impairing daily functioning and . Prevalence in the general adult population is estimated at up to 3%, but rises significantly among at-risk groups, with disorder affecting 10-38% of shift workers. Diagnosis often involves assessing the circadian phase through dim melatonin onset (DLMO) testing, which measures the timing of secretion under controlled dim conditions to identify phase shifts. , a noninvasive method using wearable devices to monitor activity patterns, may also support by revealing sleep-wake timing irregularities.

Treatment and Management

Non-Pharmacological Interventions

Non-pharmacological interventions form the cornerstone of managing dyssomnias, emphasizing behavioral modifications and environmental adjustments to improve sleep patterns without relying on medications. These approaches are recommended as first-line treatments by guidelines due to their efficacy, durability of effects, and lack of side effects. For conditions like and disorders, strategies such as and light exposure target underlying perpetuating factors, often yielding sustained improvements in sleep quality and daytime functioning. Cognitive Behavioral Therapy for Insomnia (CBT-I) is a structured, evidence-based program specifically designed to address chronic , a primary dyssomnia, through several core components. involves associating the bed with by limiting its use to and intimacy, such as leaving the if unable to within 20 minutes. Sleep restriction limits time in bed to actual time, gradually increasing it as efficiency improves, which consolidates and reduces fragmentation. challenges maladaptive thoughts about , like catastrophic worries over sleeplessness, replacing them with realistic perspectives to alleviate anxiety. Meta-analyses indicate response rates of approximately 50-80% and long-term remission rates of 30-50% in various populations, with effects persisting in follow-up assessments. Sleep hygiene education promotes foundational habits to foster optimal sleep environments and routines, applicable across dyssomnias including hypersomnias and intrinsic sleep disturbances. Key recommendations include maintaining consistent sleep and wake schedules daily, even on weekends, to stabilize the sleep-wake cycle. Optimizing the environment—keeping it cool (around 18-22°C), dark (using blackout curtains), and quiet (with if needed)—enhances sleep initiation and maintenance. Avoiding daytime naps longer than 30 minutes, limiting and heavy meals in the evening, and minimizing before bed reduce and support natural circadian alignment. Research supports these practices in improving sleep duration and quality, particularly when combined with other interventions. For circadian rhythm disorders, a subset of dyssomnias like delayed sleep phase syndrome, chronotherapy and offer targeted methods to realign internal clocks. Chronotherapy progressively delays or advances bedtime and wake time in increments until synchronization with desired schedules. Bright light therapy, typically involving 10,000 exposure for 30-60 minutes, is timed strategically—morning for advancing rhythms in advanced sleep phase or evening for delaying in delayed phase—to suppress and shift circadian phase. Clinical trials demonstrate that appropriately timed light therapy resets timing, improves sleep quality, and enhances daytime alertness. Additional modalities include relaxation techniques, strategic exercise, and emerging device-based options to augment sleep regulation. Progressive muscle relaxation, involving sequential tensing and releasing of muscle groups, reduces physiological arousal and promotes faster sleep onset; randomized trials show it significantly improves sleep quality and decreases insomnia severity. Regular aerobic exercise, preferably in the afternoon (e.g., 4-7 PM), enhances slow-wave sleep and overall sleep efficiency without disrupting nighttime rest, as vigorous evening activity may increase alertness. Device-based interventions, such as acoustic stimulation wearables that deliver timed sound pulses during non-REM sleep, boost slow-wave activity and consolidate sleep; meta-analyses confirm their efficacy in reducing insomnia symptoms and improving next-day cognitive function.

Pharmacological and Medical Treatments

Pharmacological treatments for dyssomnias primarily target specific subtypes, such as , , sleep-related breathing disorders, and sleep-wake disorders, with medications selected based on symptoms and from clinical guidelines (as per 2017, 2021, and 2024 AASM guidelines). For chronic , a common intrinsic dyssomnia, hypnotics and sedatives are used to improve onset and maintenance. Benzodiazepines like are recommended for short-term treatment of onset and maintenance difficulties, with showing reductions in by approximately 20 minutes and increases in total time by up to 64 minutes, though their use is limited due to moderate quality. Non-benzodiazepine "Z-drugs," such as , , and , are weakly recommended for similar indications, offering benefits like reduced wake after onset by 25 minutes with , but with very low quality and comparable efficacy to benzodiazepines. antagonists, including , , , and low-dose , are conditionally endorsed for maintenance , demonstrating reductions in wake after onset by 20-30 minutes, supported by low-quality . In hypersomnias like , stimulants promote wakefulness and manage . is strongly recommended for adults with to alleviate , backed by moderate-quality evidence from randomized trials showing improvements in disease severity and . , the R-enantiomer of , receives a conditional recommendation for the same indication, with moderate evidence for reducing sleepiness. is strongly recommended for adult , particularly for and disrupted nighttime sleep, with moderate evidence indicating enhancements in total sleep time and frequency reduction. For sleep-related breathing disorders classified as dyssomnias, such as , therapies serve as first-line medical interventions. (CPAP) is strongly recommended for adults with due to moderate-to-severe apnea, with high-quality evidence from 38 randomized controlled trials demonstrating significant reductions in sleepiness scores. (BiPAP) is conditionally suggested over CPAP in cases requiring higher pressures or when CPAP is poorly tolerated, supported by moderate evidence for improved adherence and symptom relief. Melatonin agonists aid in alignment for disorders like delayed -wake disorder. , a , is weakly recommended for -onset with circadian components, reducing latency by about 10 minutes based on very low-quality evidence, and is suitable for longer-term use with minimal adverse effects. Strategically timed (0.5-5 mg) is suggested for delayed -wake disorder in adults and children, with low to moderate evidence showing phase advances in timing. Across these treatments, risks include dependency with hypnotics and sedatives, next-day drowsiness, , and impairment, particularly with benzodiazepines and Z-drugs, necessitating the lowest effective dose and short-term use. For stimulants like , potential fetal harm and interactions with contraceptives are concerns, while carries risks of respiratory depression. The (AASM) guidelines emphasize monitoring for adverse effects, tolerance, and efficacy, recommending pharmacological options as adjuncts to behavioral therapies when indicated, with all recommendations graded as weak to strong based on methodology due to varying quality.

Epidemiology and Prognosis

Prevalence and Demographics

Dyssomnias, which include conditions such as , hypersomnias, and sleep-wake disorders, affect approximately 10-30% of adults worldwide. The subtype is the most common, with a global prevalence of 6-10% for the clinical disorder, while hypersomnias are rarer, estimated at 0.005-0.1% for central disorders like and . disorders affect about 1-10% of adults, often underdiagnosed due to overlap with other sleep complaints. Demographic patterns reveal significant variations in dyssomnia . Women experience a 1.5- to 2-fold higher risk of compared to men, attributed in part to hormonal fluctuations during , , and that disrupt architecture. increases with age, particularly among older adults, where sleep disturbances affect up to 50-60%, driven by changes in circadian rhythms such as advanced sleep phase and reduced sleep efficiency. Certain occupational groups, like healthcare workers, show elevated rates; for instance, disorder impacts around 20-30% of shift-working personnel in this sector due to irregular schedules. Geographic and socioeconomic trends further influence dyssomnia occurrence. Rates vary by setting; CDC data indicate higher sleep difficulties in rural/nonmetropolitan areas (e.g., 17.1% vs. 12.7% in large metros), potentially linked to and factors. In the United States, about 14.5-17.8% of adults report trouble falling or staying asleep, compared to varying figures globally. Socioeconomic disparities play a role, with limited to healthcare exacerbating underdiagnosis and untreated cases in lower-income populations. Post-pandemic studies show increased , particularly in , with up to 50% of infected individuals experiencing persistent symptoms at 6 months, and 42% at 1 year (as of 2025). Overall surges linked to and routines vary by region. As of 2025, continues to contribute, with 42% persistence at 1 year post-infection in some cohorts.

Long-Term Outcomes

Dyssomnias often persist chronically, with a significant proportion of cases lasting for years or even decades, leading to sustained disruptions in sleep architecture and daily functioning. For instance, among individuals with —a primary dyssomnia—approximately 68% report symptoms enduring five years or longer, while 85% experience persistence for at least one year. This chronicity contributes to a guarded , where untreated or poorly managed dyssomnias can exacerbate underlying vulnerabilities, though early may mitigate progression in some cases, such as through behavioral therapies that improve over time. Long-term mental health outcomes are particularly concerning, as dyssomnias heighten the risk of developing comorbid psychiatric conditions. Individuals with symptoms are approximately 2 to 3 times more likely to develop a , such as or anxiety, within the following year, with preceding mood disorders in about 50% of cases and anxiety disorders in 20%. , common in hypersomnias and certain disorders, correlates with cognitive impairments, including doubled dementia risk in elderly men, and that amplifies vulnerability to and . Physically, prolonged dyssomnias contribute to a cascade of cardiometabolic and oncologic risks due to ongoing sleep fragmentation and circadian misalignment. Chronic sleep disruption elevates risk by 20% ( 1.20) and odds by 50% ( 1.5), while doubling the likelihood of ( 1.84). Cancer incidence rises, notably for colorectal (relative risk 1.35 after 15+ years of night shifts in circadian disorders), , and types, linked to disrupted and immune function. Gastrointestinal morbidity worsens, with aggravated symptoms in conditions like . Mortality and quality-of-life trajectories reflect these cumulative burdens, with dyssomnias associated with higher all-cause death rates, such as a 69% increased hazard in men from sustained sleep restriction (hazard ratio 1.69). Excessive daytime sleepiness in hypersomnias raises fatal accident risks 2 to 3 times for road incidents and 1.9 times for occupational mishaps, while intrinsic dyssomnias like narcolepsy impair long-term vocational stability. Overall, dyssomnias accelerate aging-like biological wear, including cognitive decline and dementia risk, underscoring the need for sustained management to avert irreversible declines.

References

  1. [1]
    Dyssomnia: Causes, Types, and Symptoms - Sleep Foundation
    Dec 22, 2023 · Dyssomnia refers to the collection of sleep disorders that negatively impact the quantity and quality of sleep.Missing: authoritative | Show results with:authoritative
  2. [2]
    Primary Sleep Disorders: Dyssomnias | Johns Hopkins Medicine
    Dyssomnia sleep disorders cause difficulty falling asleep or staying asleep. An example of a dyssomnia is periodic limb movements in sleep.Missing: authoritative | Show results with:authoritative
  3. [3]
    What Are the Different Types of Dyssomnias? - WebMD
    Feb 27, 2024 · Dyssomnia is a group of common sleeping disorders that can affect your quality of sleep. Learn more about the signs, symptoms, and causes of ...Missing: authoritative | Show results with:authoritative
  4. [4]
  5. [5]
    Dyssomnias and Parasomnias in Early Childhood - AAP Publications
    May 1, 2007 · The American Academy of Sleep Medicine defines parasomnias as “undesirable physical events or experiences that occur during entry into sleep, ...
  6. [6]
    Insomnia Disorders: Nosology and Classification Past, Present, and ...
    May 14, 2021 · Three major classification systems for insomnia are the International Classification of Sleep Disorders, the International Classification of Diseases, and DSM.
  7. [7]
    AASM | International Classification of Sleep Disorders
    Aug 13, 2024 · Sleep disorders are grouped into six major categories in the ICSD-3-TR: Insomnia Disorders; Sleep-Related Breathing Disorders; Central Disorders ...
  8. [8]
  9. [9]
    None
    Below is a merged summary of the ICSD-1 (1990) Dyssomnias Classification, consolidating all information from the provided segments into a comprehensive response. To retain as much detail as possible, I will use a structured format with tables where appropriate, followed by a narrative summary. The response avoids any "thinking tokens" and focuses solely on presenting the merged information efficiently.
  10. [10]
    Classification of Sleep Disorders - PMC - PubMed Central - NIH
    In the ICSD, the term hypersomnia is diagnostic, with the preferred term for the complaint being daytime sleepiness or excessive daytime sleepiness. In the ...
  11. [11]
    International classification of sleep disorders-third edition - PubMed
    The ICSD-3 is built on the same basic outline as the ICSD-2, identifying seven major categories that include insomnia disorders, sleep-related breathing ...
  12. [12]
    Sleep Diary: How and Why You Should Keep One - Sleep Foundation
    Jun 20, 2023 · A sleep diary is a valuable tool for tracking sleep, monitoring sleep habits, and documenting sleeping problems.
  13. [13]
    Epworth Sleepiness Scale - Division of Sleep Medicine
    UNDERSTANDING YOUR SCORE ; 0–10, Normal range in healthy adults ; 11–14, Mild sleepiness ; 15–17, Moderate sleepiness ; 18 or higher, Severe sleepiness ...Missing: initial Pittsburgh
  14. [14]
    The Pittsburgh Sleep Quality Index (PSQI)
    The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire that assesses sleep quality over a one-month time interval.Missing: diagnosis Epworth
  15. [15]
    [PDF] ICSD-3-TR
    The sleep disturbance and associated daytime symptoms are not solely due to another current sleep disorder, medical disorder, mental disorder, or medication/ ...<|control11|><|separator|>
  16. [16]
    Neurobiology of the Orexin System and Its Potential Role in the ...
    Jan 24, 2022 · Evidence shows that orexins may potentiate hedonic behaviours by increasing the feeling of pleasure or reward to various signalling.
  17. [17]
    The Neurotransmitters of Sleep - PMC - PubMed Central - NIH
    Projections of these GABA neurons inhibit the firing of cells involved in wakefulness. Several groups of neurons have been shown to be inhibited by this action— ...Missing: basis dyssomnia
  18. [18]
    Sleep Neurobiology from a Clinical Perspective - Oxford Academic
    Mixed in with the orexin neurons of the lateral hypothalamus are a large number of REM sleep-active neurons that produce both MCH and GABA.189–191 These cells ...Sleep Neurobiology From A... · Introduction · Wake-Promoting Neurochemical...<|separator|>
  19. [19]
    The Genetics of Sleep Disorders in Children: A Narrative Review
    Sep 23, 2021 · HLA DQB1*0602 and DQA1*0102 are the primary susceptibility alleles for narcolepsy ... Considering that HLA-DQB1*06:02 is expressed in 86–98% of ...4. Sleep-Related Breathing... · 6. Circadian Rhythm... · 7. Parasomnias
  20. [20]
    Genomics of circadian rhythms in health and disease
    Dec 17, 2019 · In humans, mutations in circadian clocks have been associated with circadian rhythm sleep disorders. Familial advanced sleep phase disorder ...
  21. [21]
    Narcolepsy type 1: what have we learned from genetics? | SLEEP
    May 22, 2020 · The most impactful risk factor is the Human Leukocyte Antigen DQB1*06:02 variant in NT1. This genetic variant increases the risk over 20-fold ...Missing: dyssomnia heritability
  22. [22]
    The Impact of Sleep and Circadian Disturbance on Hormones and ...
    Hormones such as growth hormone, melatonin, cortisol, leptin, and ghrelin are closely associated with sleep and circadian rhythmicity, and endogenous circadian ...Missing: dyssomnia | Show results with:dyssomnia
  23. [23]
    Sleep disorders impact hormonal regulation: unravelling the ...
    Aug 1, 2025 · Cortisol not only increases the duration and intensity of NREM sleep but also inhibits REM sleep. Under normal sleep conditions, cortisol ...Missing: dyssomnia | Show results with:dyssomnia
  24. [24]
    Brain Basics: Understanding Sleep
    Feb 25, 2025 · Sleep-promoting cells within the hypothalamus and the brain stem produce a brain chemical called GABA, reduces activity in the hypothalamus and ...Missing: dyssomnia | Show results with:dyssomnia
  25. [25]
    Hypothalamic Regulation of Sleep | Neuropsychopharmacology
    Nov 1, 2001 · In this chapter we review the recent evidence identifying hypothalamic sleep and wake neurotransmitter populations and propose that the hypothalamus plays a ...Missing: neurological dyssomnia
  26. [26]
    Biological and Clinical Implications of Comorbidities in Parkinson's ...
    Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD.Missing: dyssomnia | Show results with:dyssomnia
  27. [27]
    Thyroid Dysfunction and Risk of Parkinson's Disease - Frontiers
    This systematic review and meta-analysis found a significant association of both hypothyroidism and hyperthyroidism with an increased risk of PD.
  28. [28]
    Thyroid Disorders as a Risk Factor for Neurodegenerative ...
    Mar 26, 2025 · Conclusions: Thyroid disorders are significantly associated with an increased risk of several neurodegenerative diseases. Thyroidectomy may have ...
  29. [29]
    Technology in the Bedroom - Sleep Foundation
    Jul 11, 2025 · As best as possible, avoid using electronics for an hour or more before you plan to go to bed. Put devices in a drawer: By not having a phone ...
  30. [30]
    Youth screen media habits and sleep - PubMed Central - NIH
    Avoid screen media in the hour before bedtime and at nighttime. Replace evening screen time with calm activities for your children (reading, coloring, ...
  31. [31]
    Caffeine Effects on Sleep Taken 0, 3, or 6 Hours before Going to Bed
    The results of this study suggest that 400 mg of caffeine taken 0, 3, or even 6 hours prior to bedtime significantly disrupts sleep. Even at 6 hours, caffeine ...
  32. [32]
    Sleep, Sleepiness, and Alcohol Use - PMC - PubMed Central - NIH
    This article provides an overview of alcohol's effects on normal sleep, sleep physiology, and daytime alertness in nonalcoholic people.Normal Sleep Physiology · Stages Of Nrem And Rem Sleep · Relation Of Nocturnal Sleep...
  33. [33]
    Environmental noise and sleep disturbances: A threat to health? - NIH
    It has also been proven that nocturnal noise pollution significantly impairs sleep, objectively and subjectively.
  34. [34]
    Light pollution and human health and wellness | DarkSky International
    Nov 3, 2025 · Shift sleep/wake cycles: Artificial light can confuse our internal clocks, potentially leading to sleep disturbances. Cause changes at the ...
  35. [35]
    Study suggests light pollution may cause insomnia in older adults
    May 21, 2019 · A variety of environmental factors, including excessive noise or light and extreme temperatures, will disrupt the sleep of most individuals.
  36. [36]
    Sleep Disorder - StatPearls - NCBI Bookshelf
    Sleep disorders are a group of conditions that disturb normal sleep patterns. Sleep disorders are one of the most common clinical problems encountered.Missing: III | Show results with:III
  37. [37]
    Sleep disorders - Symptoms and causes - Mayo Clinic
    Sep 10, 2024 · Symptoms · Being very sleepy during the daytime. · Trouble falling asleep, waking up during the night and not being able to go back to sleep.Missing: dyssomnia | Show results with:dyssomnia
  38. [38]
    Long Working Hours and Sleep Disturbances: The Whitehall II ... - NIH
    Working long hours appears to be a risk factor for the development of shortened sleeping hours and difficulty falling asleep.
  39. [39]
    Association of Sleep Duration, Napping, and Sleep Patterns With ...
    Jul 26, 2022 · Accumulating evidence showed that genetic and early‐life environmental factors (such as natural environment, fetal environment, childhood ...Missing: dyssomnia | Show results with:dyssomnia<|control11|><|separator|>
  40. [40]
    Narcolepsy - StatPearls - NCBI Bookshelf
    Prevalence is 14 per 100,000 people for narcolepsy type 1 and 65.4 per 100,000 people for narcolepsy type 2. Incidence is highest in the late teens to early ...
  41. [41]
    Idiopathic hypersomnia - Orphanet
    A rare neurologic disease characterized by an excessive daytime sleepiness with long and unrefreshing naps, and/or prolonged and undisturbed nocturnal sleep.
  42. [42]
    Restless legs syndrome - Symptoms and causes - Mayo Clinic
    making you drag through your day. These therapies calm the restlessness and ...
  43. [43]
    Periodic Limb Movements of Sleep (PLMS): Causes & Symptoms
    Periodic limb movements of sleep (PLMS) is a movement disorder that involves repetitive leg and/or arm movements during sleep, which can disrupt your sleep.Missing: intrinsic | Show results with:intrinsic
  44. [44]
    Narcolepsy: Causes, Symptoms, & Treatments - Sleep Foundation
    Jul 25, 2025 · Narcolepsy is relatively rare. NT1 affects between 20 and 67 people per 100,000 in the United States. According to a population based study in ...
  45. [45]
    Diagnosis and treatment of sleep disorders: a brief review for clinicians
    Insomnia assessment tools can utilize self-reporting methods (sleep diary and Pittsburgh Sleep Quality Index) and objective methods include actigraphy and PSG.
  46. [46]
    Environmental and behavioral sleep disorders | MedLink Neurology
    Extrinsic sleep disorders are those that result in sleep disruption or excessive daytime sleepiness from causes that arise outside the body. This contrasts with ...
  47. [47]
    TREATMENT OPTIONS FOR SLEEP DISTURBANCES DURING ...
    Sleep disturbances are extremely common in the early stages of recovery from alcohol dependence and may persist for several months despite continued abstinence.
  48. [48]
    Night-time exogenous melatonin administration may be a beneficial ...
    Sleep disorders are the common side effects of beta blockers. Beta blockers have been shown to reduce the production of melatonin via specific inhibition of ...<|control11|><|separator|>
  49. [49]
    Circadian Rhythm Sleep Disorders - PMC - PubMed Central
    CRSDs are caused by alterations of the central circadian time-keeping system, or a misalignment of the endogenous circadian rhythm and the external environment.
  50. [50]
    Circadian Rhythm Sleep–Wake Disorders: a Contemporary Review ...
    Circadian rhythm disorders emerge when the internal biological clock is not in sync with the external environment. Disruption of the natural circadian rhythm ...
  51. [51]
    Effects of light on human circadian rhythms, sleep and mood - PMC
    Aug 20, 2019 · Our circadian pacemaker, the suprachiasmatic nuclei (SCN) in the hypothalamus, is entrained to the 24-hour solar day via a pathway from the ...
  52. [52]
    Circadian Rhythm Abnormalities - PMC - PubMed Central - NIH
    The timing of melatonin secretion by the pineal gland is regulated by the SCN, with the onset of secretion approximately 2 hours before natural sleep time and ...
  53. [53]
    Delayed sleep–wake phase disorder and its related sleep behaviors ...
    May 19, 2023 · Delayed sleep–wake phase disorder (DSWPD) is a sleep disorder in which the habitual sleep–wake timing is delayed, resulting in difficulty in ...
  54. [54]
    Therapeutics for Circadian Rhythm Sleep Disorders - PMC
    Circadian rhythm sleep disorders arise when there is a misalignment between the timing of the endogenous circadian rhythms and the external environment or when ...
  55. [55]
    Jet Lag and Shift Work Disorder - PubMed
    The prevalence of jet lag disorder is unclear, approximately 5%-10% of shift workers have shift work disorder. Treatment aims to realign the internal circadian ...
  56. [56]
    A Clinical Approach to Circadian Rhythm Sleep Disorders - PMC
    Circadian rhythm sleep disorders are characterized by complaints of insomnia and excessive sleepiness that are primarily due to alterations in the internal ...Missing: definition | Show results with:definition
  57. [57]
    Circadian Rhythm Sleep Disorders - PMC - NIH
    Survey studies suggest that up to 3% of the adult population suffers from a circadian rhythm sleep disorder (CRSD). However, these sleep disorders are often ...
  58. [58]
    Shiftwork-Mediated Disruptions of Circadian Rhythms and Sleep ...
    It is 10–38% prevalent in shift workers [5, 43]. The disturbance in general is the sleep-wake cycle distortion of extrinsic origin. This disorder is related to ...
  59. [59]
    Dim light melatonin onset (DLMO): a tool for the analysis of circadian ...
    DLMO is useful for determining whether an individual is entrained (synchronized) to a 24-h light/dark (LD) cycle or is in a free-running state.
  60. [60]
    OBJECTIVE DIAGNOSIS OF CIRCADIAN RHYTHM DISORDERS
    Circadian rhythm sleep-wake disorders (CRSWDs) are characterized by a misalignment between the desired timing of sleep and the ability to fall asleep and remain ...
  61. [61]
    We know CBT-I works, now what? - PMC - NIH
    Feb 1, 2022 · Cognitive behavioral therapy for insomnia (CBT-I) has been shown to be efficacious and now is considered the first-line treatment for insomnia.
  62. [62]
    Cognitive-Behavioral Therapy for Insomnia: An Effective and ... - NIH
    CBT-i produces results that are equivalent to sleep medication, with no side effects, fewer episodes of relapse, and a tendency for sleep to continue to improve ...
  63. [63]
    Cognitive Behavioral Therapy for Insomnia (CBT-I): A Primer - PMC
    Conclusion and Further Training. There is an overwhelming preponderance of evidence that CBT-I is an efficacious treatment for chronic insomnia [15; 38].
  64. [64]
    The Efficacy of Cognitive Behavioral Therapy for Insomnia in ...
    In the present study the efficacy of CBT-I was assessed in patients with chronic pain. Pre-Post changes for sleep continuity, pain and mood were assessed across ...<|control11|><|separator|>
  65. [65]
    Success Rate of Cognitive Behavioral Therapy for Insomnia in ...
    Aug 19, 2025 · Cognitive Behavioral Therapy for Insomnia (CBT-I) has a success rate of approximately 70-80% in highly motivated patients, with clinically ...Missing: percentage | Show results with:percentage
  66. [66]
    Management of sleep disorders among children and adolescents ...
    Paediatric insomnia has been defined as “repeated difficulty with sleep initiation, duration, consolidation, or quality that occurs despite age-appropriate time ...Sleep Physiology · Non-Pharmacological/behavioural... · MelatoninMissing: dyssomnia | Show results with:dyssomnia
  67. [67]
    Treatment of circadian rhythm sleep disorders with light - PubMed
    Appropriately-timed exposure to bright light can reset the timing of sleep and wake to the desired times, and improve sleep quality and daytime alertness.
  68. [68]
    Treatment of Circadian Rhythm Sleep–Wake Disorders - PMC
    The main clinical manifestations are insomnia and excessive daytime sleepiness that often lead to clinically meaningful distress or cause mental, physical, ...Missing: dyssomnia | Show results with:dyssomnia
  69. [69]
    Effectiveness of Progressive Muscle Relaxation, Deep Breathing ...
    Results showed that progressive muscle relaxation, deep breathing, and guided imagery all increased the state of relaxation for participants in those groups.
  70. [70]
    Progressive muscle relaxation increases slow‐wave sleep during a ...
    Mar 30, 2022 · Research supports their efficacy in decreasing physiological arousal, stress, reducing self‐reported anxiety, and improving self‐reported sleep ...
  71. [71]
    The Effect of Physical Activity on Sleep Quality and Sleep Disorder
    Aug 16, 2023 · Therefore, the timing of exercise is vital, with some evidence suggesting that morning or afternoon exercise may be more beneficial for sleep ...
  72. [72]
    A systematic review and meta-analysis of acoustic stimulation in the ...
    Jun 12, 2025 · Acoustic stimulation is an effective and safe treatment for insomnia, offering significant improvements in sleep quality, severity, and overall health, with ...
  73. [73]
    Clinical Practice Guideline for the Pharmacologic Treatment of ...
    The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults.Missing: dyssomnia | Show results with:dyssomnia
  74. [74]
    Treatment of central disorders of hypersomnolence
    This clinical practice guideline updates the previously published American Academy of Sleep Medicine (AASM) practice parameters on the treatment of narcolepsy ...
  75. [75]
    Treatment of Adult Obstructive Sleep Apnea with Positive Airway ...
    This guideline establishes clinical practice recommendations for positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA) in adults.
  76. [76]
    [PDF] Clinical Practice Guideline for the Treatment of Intrinsic Circadian ...
    During a symptomatic period, the time of high sleep propensity gradually shifts, such that patients experience daytime hypersomnolence and nighttime insomnia. ...Missing: dyssomnia | Show results with:dyssomnia
  77. [77]
    Prevalence of chronic insomnia in adult patients and its correlation ...
    Various studies worldwide have shown the prevalence of insomnia in 10%–30% of the population, some even as high as 50%–60%. It is common in older adults ...
  78. [78]
    The Prevalence of Insomnia Disorder in the General Population: A ...
    May 14, 2025 · They observed that 10%–15% of the population reported insomnia with daytime symptoms, and 6%–10% suffered from insomnia according to the strict ...
  79. [79]
    Central Disorders of Hypersomnolence - DynaMed
    Incidence/Prevalence​​ The prevalence of idiopathic hypersomnia is estimated to be around 0.002%-0.01%, with a mean age of onset at about 16-21 years.Missing: global | Show results with:global
  80. [80]
    Circadian Rhythm Sleep–Wake Disorders in Older Adults - PMC
    All circadian rhythm sleep-wake disorders are characterized by an inability to fall asleep, remain asleep, and/or awaken at the desired or required time.Missing: definition | Show results with:definition
  81. [81]
    Women Have Higher Rates of Insomnia Than Men Throughout Their ...
    Jul 18, 2025 · Physiological, hormonal, psychological, social and environmental factors contribute to the higher prevalence of insomnia disorder in the female ...
  82. [82]
    Women's Sleep: Neurobiological & Hormonal Mechanisms
    Women are 41% more likely than men to experience insomnia, and this risk ... The menopausal transition is associated with heightened prevalence of insomnia and ...
  83. [83]
    Sleep disorders in the elderly: a growing challenge - PubMed
    The prevalence of sleep disorders is higher among older adults. Loud snoring, which is more common in the elderly, can be a symptom of obstructive sleep apnoea.
  84. [84]
    The prevalence of sleep loss and sleep disorders in young and old ...
    Almost 50–60 % of elderly population suffer from sleep disorders such as sleep apnea, restless legs syndrome, REM sleep behavior disorder, etc.
  85. [85]
    Shift-work sleep disorder among health care workers at public ...
    Jul 8, 2022 · Shift-work sleep disorder was estimated to be 20%-30% among shift workers [2]. Approximately 10% of the USA workforce meets the criteria for ...
  86. [86]
    Sleep Difficulties in Adults: United States, 2020 - CDC
    Jun 22, 2022 · Women (20.7%) were more likely than men (14.7%) to have trouble staying asleep. Non-Hispanic White adults (21.0%) were more likely to have ...Missing: dyssomnia | Show results with:dyssomnia
  87. [87]
    Living in urban or rural environments affect the sleep quality of ... - NIH
    May 18, 2024 · In this regard, the results of Mandal et al.'s study (2018) showed that the prevalence of poor-quality sleep is higher in the urban population ...
  88. [88]
    Insomnia Facts and Stats - Healthline
    Nov 7, 2024 · Prevalence of insomnia. Prevalence of ... Researchers found a 37 percent increase in clinical insomnia from before the pandemic to its peak.
  89. [89]
    Prevalence and associations of insomnia after COVID-19 infection
    The prevalence of significant insomnia at the initial visit was 50% and 42% at the subsequent visit (obtained in 78 of the 280 patients). Lower age, female sex, ...
  90. [90]
    Dyssomnia: Impact on Medical Diseases and Morbidity - Sleep-EVAL
    Dec 1, 2011 · They found that subjects with insomnia symptoms were 4-8 times more likely to develop a mental disorder during the year following the onset of ...
  91. [91]
    Short- and long-term health consequences of sleep disruption - PMC
    May 19, 2017 · Short-term consequences of sleep disruption include increased stress responsivity; somatic problems; reduced quality of life (QoL); emotional ...
  92. [92]
    Sleep Deprivation, Sleep Disorders, and Chronic Disease - CDC
    Aug 31, 2023 · Additionally, emerging evidence links sleep deprivation to adverse cardiometabolic health and cognitive health and an increased risk of dementia ...